On October 8, AKESO fell 3.02% in regular trading to HK$105.5, with turnover of HK$872 million. The decline came as the biotechnology sector extended its previous session's pullback, with short-term profit-taking continuing to weigh on innovative drug names.

Background context shows the Hang Seng Biotechnology Index had slumped 3.15% on October 7, while Genscript Biotech plunged over 14%, marking a sharp deterioration in sector sentiment. AKESO, a core innovative drug play, had rallied on AstraZeneca's US$2 billion strategic investment in Summit Therapeutics and positive clinical progress for ivonescimab, leaving the stock vulnerable to near-term profit-taking.

Within the biotechnology sector, Innovent Bio fell 3.74%, Beone Medicines slipped 1.29%, 3SBio dropped 4.27%, Cansinobio declined 2.11%, and HBM Holdings-B tumbled 7.96%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)